- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Rethinking Uncomplicated UTI Treatment: Discussion of Aminoglycosides as an Alternative to Carbapenems
An expert briefly describes the study ‘Single Dose Aminoglycosides versus Carbapenems for the Treatment of Uncomplicated Urinary Tract Infections Caused by Extended-Spectrum β-lactamase-phenotype Gram-negative Enterobacterales,” including its objective, design, methodology, results, and key takeaways, and discusses how this data impacts the treatment of inpatient uncomplicated UTIs caused by extended-spectrum β-lactamase-producing Enterobacterales
EP: 1.Unmet Needs in the Management of UTIs
EP: 2.Gepotidacin vs Nitrofurantoin in uUTI: Study Overview and Clinical Implications
EP: 3.Rethinking Uncomplicated UTI Treatment: Discussion of Aminoglycosides as an Alternative to Carbapenems
EP: 4.Comparing Treatment Options for Acute Pyelonephritis From a Meta-Analysis
EP: 5.Addressing Unmet Needs and Future Outlooks in Treatment of Uncomplicated UTI
Video content above is prompted by the following:
- Briefly describe the study “Single Dose Aminoglycosides versus Carbapenems for the Treatment of Uncomplicated Urinary Tract Infections Caused by Extended-spectrum β-lactamase-phenotype Gram-negative Enterobacterales.”
- What was the objective of this study?
- How was this study designed, and what methodology was used?
- What results were presented?
- Provide your key takeaways from this study. How does this data impact how you treat inpatient UTIs caused by extended-spectrum β-lactamase-producing Enterobacterales?
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Variable Long COVID Definitions Create Hurdles in Care, Research
August 12th 2025There is a need to consolidate various long COVID definitions to establish a standardized definition that ensures consistent recognition, documentation, diagnosis, and treatment, according to new research.
Read More
Bird Flu Risks, Myths, and Prevention Strategies: A Conversation With the NFID's Dr Robert Hopkins
January 21st 2025Joining us for this episode of Managed Care Cast is Robert H. Hopkins Jr, MD, medical director at the National Foundation for Infectious Diseases (NFID), who will help separate fact from fiction about avian influenza and discuss what needs to be done to prevent a future escalation.
Listen
Prenatal PFAS Exposure Alters Infant Vaccine-Related Immune Cells
August 1st 2025Prenatal exposure to per- and polyfluoroalkyl substances (PFAS), a class of persistent environmental pollutants, was linked to significant shifts in infant T helper cell development, raising concerns about long-term effects on vaccine response, immune regulation, and disease susceptibility.
Read More
Updated mRNA Vaccines Against JN.1 Show Strong Safety Signal in Real-World Data
July 31st 2025A nationwide Danish cohort study demonstrated no increased risk of serious adverse events following vaccination with JN.1-updated mRNA COVID-19 vaccines, reinforcing their safety profile and supporting continued use in high-risk populations amid ongoing viral evolution.
Read More
